Shares of Endo International plc – (NASDAQ:ENDP) (TSE:ENL) have been given a consensus rating of “Hold” by the twenty-four ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, sixteen have given a hold recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $11.36.

Several brokerages have commented on ENDP. Mizuho restated a “buy” rating and issued a $14.00 target price (down previously from $19.00) on shares of Endo International in a research note on Tuesday, September 12th. ValuEngine upgraded Endo International from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Goldman Sachs Group began coverage on Endo International in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 target price for the company. Zacks Investment Research downgraded Endo International from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $9.00 target price on shares of Endo International in a research note on Sunday, September 17th.

Shares of Endo International (NASDAQ ENDP) traded down $0.13 during midday trading on Friday, reaching $8.73. The company’s stock had a trading volume of 5,377,100 shares, compared to its average volume of 6,940,833. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $17.63. The company has a current ratio of 1.08, a quick ratio of 0.86 and a debt-to-equity ratio of 10.78. The company has a market cap of $1,950.00, a P/E ratio of -0.45, a P/E/G ratio of 2.99 and a beta of 0.59.

Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.85 by $0.06. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The business had revenue of $786.90 million during the quarter, compared to the consensus estimate of $794.93 million. During the same quarter last year, the company earned $1.01 EPS. The firm’s revenue was down 11.0% compared to the same quarter last year. equities research analysts predict that Endo International will post 3.67 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of ENDP. Comerica Bank boosted its position in shares of Endo International by 1.2% during the 2nd quarter. Comerica Bank now owns 155,786 shares of the company’s stock valued at $1,818,000 after acquiring an additional 1,905 shares during the last quarter. Blair William & Co. IL purchased a new position in shares of Endo International during the 2nd quarter valued at about $126,000. Airain ltd purchased a new position in shares of Endo International during the 2nd quarter valued at about $387,000. Schroder Investment Management Group purchased a new position in shares of Endo International during the 2nd quarter valued at about $330,000. Finally, Systematic Financial Management LP raised its holdings in shares of Endo International by 14.6% during the 2nd quarter. Systematic Financial Management LP now owns 149,485 shares of the company’s stock valued at $1,670,000 after buying an additional 19,065 shares in the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Endo International plc – (ENDP) Given Average Rating of “Hold” by Analysts” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/endo-international-plc-endp-given-average-rating-of-hold-by-analysts.html.

Endo International Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.